1.. Introduction {#sec1}
================

Antibodies, also called immunoglobulins (Igs), comprise two identical light chains and heavy chains linked by disulfide bonds. The light chain contains a variable (V~L~) domain and a constant (C~L~) domain. The heavy chain has four to five domains, depending on the isotype, including a variable (V~H~) domain and several constant (C~H~) domains: three C~H~ domains in IgG, IgA and IgD and four C~H~ domains in IgM and IgE. The antigen-binding fragment (Fab) consists of the light chain (V~L~ and C~L~) and the first two domains of the heavy chain (V~H~ and C~H1~) and is specifically involved in antigen binding. The Ig Fc (fragment crystallizable) portion consists of two constant domains, namely C~H~2 and C~H~3, from each heavy chain and binds to effector molecules in order to elicit host responses. C~H~2 is the only antibody domain that exhibits very weak carbohydrate-mediated interchain protein--protein inter­actions, in contrast to the extensive interactions that occur between V~H~--V~L~, C~L~--C~H~1 and C~H~3--C~H~3 domains as seen in intact antibody structures. The crystal structures of intact IgG (Larson *et al.*, 1991[@bb17]; Harris *et al.*, 1992[@bb10], 1998[@bb11]; Saphire *et al.*, 2001[@bb26]) and Fc (Krapp *et al.*, 2003[@bb16]) reveal that the C~H~2 domain interacts with the other C~H~2 domain through sugar moieties only. The N-linked glycosylation at Asn297 of the C~H~2 domain is conserved in all mammalian IgG molecules and the homologous regions of IgM, IgD and IgE. From a functional point of view, the C~H~2 domain contains large portions of the entire binding sites for complement and Fc receptors that are critical for the effector function of antibodies (Vidarsson & van de Winkel, 1998[@bb30]; Woof & Burton, 2004[@bb32]) as well as for binding to the neonatal Fc receptor (Martin *et al.*, 2001[@bb19]), which is important for the preservation of antibody stability. The isolation and characterization of a C~H~2 domain from myeloma IgG was reported quite early on as this domain is involved in complement activity (Seon & Pressman, 1975[@bb27]). Previously, a series of amino-acid substitutions in the C~H~2 domains of various IgG subclasses was carried out to enhance the differential affinity for the Fc receptor (Canfield & Morrison, 1991[@bb2]). In the crystal structures of IgG1 Fc--FcγIII receptor complexes, Fc receptor (FcγR) exclusively interacts through the C~H~2 domains of IgG1 Fc, in which the binding site includes the Asn297 residue of the C~H~2 domain (Sondermann *et al.*, 2000[@bb28]; Radaev *et al.*, 2001[@bb24]). Several recent studies have also been focused on the characterization of the antibody constant domains, C~H~2 and C~H~3, in order to understand the folding and stability mechanisms of these domains (Demarest *et al.*, 2004[@bb4]; Feige *et al.*, 2004[@bb8]; McAuley *et al.*, 2008[@bb18]). Of these, kinetic studies exploring the folding mechanism of the C~H~2 domain suggested that an unglycosylated murine C~H~2 domain is a monomer with relatively low stability (Feige *et al.*, 2004[@bb8]). Although several crystal structures are available of intact IgG (Larson *et al.*, 1991[@bb17]; Harris *et al.*, 1992[@bb10], 1998[@bb11]; Saphire *et al.*, 2001[@bb26]), Fc (Krapp *et al.*, 2003[@bb16]; Matsumiya *et al.*, 2007[@bb20]), Fab fragments (Stanfield *et al.*, 2006[@bb29]) and variable antibody domains V~H~ or V~L~ (Dottorini *et al.*, 2004[@bb6]; Park *et al.*, 2008[@bb23]), there are no structures of the C~H~2 domain. Such a structure would allow us to determine the structural details in the absence of glycosylation and other antibody domains. Here, we present the crystal structure of an isolated un­glycosylated C~H~2 antibody domain. The isolated C~H~2 domain is a monomer and is similar to the C~H~2-domain structures embedded in the intact Fc, IgG and Fc receptor complex despite the absence of extensive interactions with sugar moieties and its isolation from other antibody domains. However, certain differences do exist which could be important in the use of such domains as scaffolds for high-affinity binders.

High-affinity binders based on variable domains (also termed domain antibodies; dAbs; Holt *et al.*, 2003[@bb13]) have attracted much attention in recent years owing to their small size and stability, which are suitable for targeting the sterically confined binding sites on antigens or other protein surfaces. Since the unglycosylated antibody C~H~2 domain appears to be a stable monomer and to be structurally independent, it might be useful as an alternative to domain antibodies for the generation of high-affinity binders. Therefore, the structure may be useful for optimization of the antibody C~H~2-domain stability, creation of alternative antibody scaffolds based on the C~H~2 domain (nanoantibodies) and as a small structural scaffold in protein design. Also, the use of C~H~2 as a scaffold is much easier and cost-effective if expressed in bacteria that do not support glycosylation.

2.. Materials and methods {#sec2}
=========================

2.1.. Cloning, protein expression and purification {#sec2.1}
--------------------------------------------------

The gene encoding the C~H~2 antibody domain was obtained by PCR amplification using the cDNA of the MAK33 γ~1~ heavy chain as a template. Protein preparation and purification were carried out as previously described (Zhang *et al.*, 2004[@bb33]).

2.2.. Size-exclusion chromatography {#sec2.2}
-----------------------------------

Purified C~H~2 was loaded onto a Superdex75 10/300 GL column that had been pre-equilibrated with phosphate-buffered saline (PBS). The protein was eluted with PBS at 0.5 ml min^−1^. The Superdex75 column was calibrated with protein molecular-weight standards of 669.0, 440.0, 232.0, 158.0, 67.0, 44.0, 25.0 and 13.7 kDa.

2.3.. Crystallization, data collection and structure determination {#sec2.3}
------------------------------------------------------------------

High-throughput screening of crystallization conditions was carried out with a Hydra II Plus crystallization robot (Matrix Technologies, Hudson, New Hampshire, USA) using the Crystal Screen kit from Hampton Research (Laguna Niguel, California, USA). Thin plate-shaped crystals were grown from a crystallization condition consisting of 30% PEG 1500 with equal volumes of protein and well solutions. The crystals were cryoprotected with the well solution after 25% glycerol had been introduced. The diffraction data were collected on the SER-CAT 22-ID beamline of the Advanced Photon Source (APS), Argonne National Laboratory. Data were processed and scaled with the *HKL*-2000 program suite (Otwinowski & Minor, 1997[@bb22]). Data-collection statistics are given in Table 1[▶](#table1){ref-type="table"}. The structure of the C~H~2 antibody domain was solved by molecular replacement with the *CCP*4 version of *AMoRe* (Navaza, 2001[@bb21]) using the C~H~2-domain structure extracted from the intact antibody IgG b12 structure (Saphire *et al.*, 2001[@bb26]; PDB code [1hzh](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1hzh)) as a search model. The initial model obtained from molecular replacement was iteratively refined using *CNS* (Brünger *et al.*, 1997[@bb1]) and rebuilt with *Coot* (Emsley & Cowtan, 2004[@bb7]) and *O* (Jones *et al.*, 1991[@bb15]). Water molecules were added automatically using *CNS* followed by visual inspection and refinement. The refinement statistics are presented in Table 1[▶](#table1){ref-type="table"}. Figures were prepared with *PyMOL* (DeLano, 2002[@bb3]).

3.. Results and discussion {#sec3}
==========================

3.1.. Structure of the isolated unglycosylated C~H~2 domain {#sec3.1}
-----------------------------------------------------------

We used recombinant DNA techniques to express the C~H~2 domain of an antibody (IgG) in *Escherichia coli* and purified the protein, which resulted in the production of the isolated unglycosylated C~H~2 domain with a molecular weight of 12 kDa. Crystals appeared in 30% PEG 1500 within a week and grew as large plates that were suitable for X-ray diffraction. The crystal structure of the C~H~2 domain was determined at 1.7 Å resolution by molecular replacement using the glycosylated C~H~2 domain from the structure of an intact antibody IgG b12 determined previously at 2.7 Å resolution (Saphire *et al.*, 2001[@bb26]). A summary of X-ray data-collection and refinement statistics is presented in Table 1[▶](#table1){ref-type="table"}. The asymmetric unit contained one C~H~2 domain and the final model included a total of 107 amino-acid residues, with more than 95% of residues in the most favored region of the Ramachandran plot (Ramachandran & Sasisekharan, 1968[@bb25]). A ribbon diagram of the unglycosyl­ated C~H~2 antibody domain is shown in Fig. 1[▶](#fig1){ref-type="fig"}(*a*), with a color coding corresponding to the *B*-factor values: blue for lower (∼11 Å^2^), green for medium (∼23 Å^2^) and red for higher (∼48 Å^2^) values. The overall structure is similar to the intact glycosylated C~H~2 domain as found in the Fc and IgG antibody structures (Figs. 1[▶](#fig1){ref-type="fig"} *b* and 1[▶](#fig1){ref-type="fig"} *c*), displaying a stable immunoglobulin fold with minor differences in the loop regions, the termini and the orientations of side chains of the binding site or surface-exposed residues. No significant intermolecular interactions that warrant the consideration of oligomerization are ob­served in the crystal lattice, which is in agreement with our size-exclusion chromatography data suggesting that the protein exists as a monomer in solution (Fig. 2[▶](#fig2){ref-type="fig"}). Our current data combined with the previous results from thermodynamic studies on the C~H~2 domain of an IgG antibody (Feige *et al.*, 2004[@bb8]) have confirmed that the isolated un­glycosylated C~H~2 domain is a stable mono­mer in the absence of glycosyl­ation and other antibody domains.

3.2.. Structural comparisons of the C~H~2 domain with intact Fc, IgG and Fc receptor complex structures {#sec3.2}
-------------------------------------------------------------------------------------------------------

To analyze the conformational features of the isolated C~H~2 domain, we compared it with recent crystal structures of human IgG Fc fragments with and without a fucose residue attached to the sugar moieties at Asn297 (Matsumiya *et al.*, 2007[@bb20]; PDB codes [2dts](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=2dts) and [2dtq](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=2dtq)), intact IgG b12 (Saphire *et al.*, 2001[@bb26]; PDB code [1hzh](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1hzh)) and Fc receptor complexes (Sondermann *et al.*, 2000[@bb28]; Radaev *et al.*, 2001[@bb24]; PDB codes [1e4k](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1e4k), [1t83](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1t83) and [1t89](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1t89)). The two C~H~2 domains in these antibody structures interact with each other through sugar moieties. Superposition of the unglycosylated C~H~2 domain on the corresponding C~H~2 domains of Fc and IgG yielded root-mean-square deviations (r.m.s.d.s) of 0.5 and 0.6 Å, respectively (Figs. 1[▶](#fig1){ref-type="fig"} *b* and 1[▶](#fig1){ref-type="fig"} *c*). This clearly indicates that glycan removal as well as isolation of the domain does not affect the structural integrity of the monomeric C~H~2 antibody domain. Furthermore, we superimposed the C~H~2 antibody domain with the C~H~2 regions of FcγRIII--Fc complex structures available in three different crystal forms and found that the r.m.s.d.s ranged from 0.5 to 1.0 Å (Fig. 3[▶](#fig3){ref-type="fig"} *a*). In all three reported FcγRIII--Fc complexes, the D/E loop (residues 296--299 between β-strands D and E) of the C~H~2 domain in Fc directly makes critical intermolecular inter­actions with the FcγRIII receptor. However, in the ortho­rhombic form only (PDB code [1t83](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1t83)), Tyr296 of the D/E loop in the C~H~2 protrudes out at the tip and makes contacts with Lys128 and Asp129 of FcγRIII (in magenta; Fig. 3[▶](#fig3){ref-type="fig"} *b*). In the two hexagonal forms of the FcγRIII--Fc complexes, Tyr296 in the D/E loop has a different conformation (blue and orange in Fig. 3[▶](#fig3){ref-type="fig"} *b*), which suggests a requirement for conformational flexibility of Tyr296 for the binding of C~H~2 to FcγRIII. When we overlaid the isolated C~H~2 domain on these complex structures (in green; Fig. 3[▶](#fig3){ref-type="fig"} *b*), we observed that Tyr296 of the isolated C~H~2 domain exhibited an upright conformation with the hydroxyphenyl side chain pointing out of the D/E loop at the tip as found in the Fc receptor complex structure of the orthorhombic form. The other C~H~2 domain of Fc region in the complex also makes interactions with the FcγRIII receptor through its F/G loop (residues 325--331 between β-strands F and G), where Pro329 of the C~H~2 domain is sandwiched by Trp90 and Trp113 of the receptor, which is also observed in the orthorhombic structure (Fig. 3[▶](#fig3){ref-type="fig"} *c*). This Fc receptor-binding site on the C~H~2 domain is structurally well conserved, in contrast to the other binding site where Tyr296 of the D/E loop exhibits significant conformational flexibility. From these structural analyses, we found that the isolated unglycosylated C~H~2 domain has a similar conformation to that embedded in the intact Fc and IgG structures. However, a significant variation was noted in the Fc receptor-binding sites when compared with the FcγRIII--Fc complexes, particularly at residue Tyr296 of the C~H~2 domain.

Isolated antibody fragments can be used as scaffolds for binders. The smallest functional antigen-binding fragment of an antibody, a variable domain, either V~H~ or V~L~, has been used successfully. From the structural point of view, the major difference between the variable and constant domains is the connecting loops between the β-strands. The complementarity-determining region (CDR) loops in the variable domains that make contacts with the antigen are longer than those found in the constant domains which interact with effector molecules. Using the structural details together with *in vitro* phage-display selection (Weiss & Penner, 2008[@bb31]; Dimitrov & Marks, 2008[@bb5]) and computational protein-loop design (Hu *et al.*, 2007[@bb14]), the C~H~2 domain could be engineered to have predetermined specificities for various antigens and proteins. In general, the Ig fold is shared by many evolution­arily unrelated or distantly related proteins (Halaby *et al.*, 1999[@bb9]). A DALI database search (Holm & Sander, 1998[@bb12]) using the C~H~2-domain fragment resulted in more than 470 different protein structures with a *Z* score greater than 2, mainly of immune-system and cell-adhesion molecules. Therefore, the scope for protein design using the antibody C~H~2-domain template may have wider applications in addition to thera­peutic high-affinity binders and stable structural scaffolds.

Supplementary Material
======================

PDB reference: [antibody C~H~2 domain, 3dj9, r3dj9sf](3dj9)
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![Structure of the C~H~2 antibody domain and structural comparison with the corresponding region in the Fc and IgG structures. (*a*) Ribbon diagram of the isolated unglycosylated C~H~2 domain from IgG γ1 is shown with a gradient ramp of colors according to the temperature factors (*B* factors): blue for lower (∼11 Å^2^), green for medium (∼23 Å^2^) and red for higher (∼48 Å^2^) values. The N- and C-­termini as well as strands A--G are marked. (*b*) The isolated C~H~2 domain (green) was superimposed with a least-squares algorithm using the C^α^ traces of the C~H~2 domains of fucosylated (blue; PDB code [2dtq](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=2dtq)) and nonfucosylated (purple; PDB code [2dts](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=2dts)) Fc structures. (*c*) Superposition of the isolated C~H~2 structure (green) with that of C~H~2 portions of an intact IgG (PDB code [1hzh](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1hzh)) using the C^α^-trace alignment. The heavy and light chains of IgG are shown in red and blue, respectively. The carbohydrate moieties between the C~H~2 domains of the Fc and IgG structures in (*b*) and (*c*) are omitted for clarity.](d-64-01062-fig1){#fig1}

![A sample of purified C~H~2 was analyzed on Superdex75 10/300 GL column calibrated with molecular-weight standards. The arrows indicate the positions where the 43.0, 25.0 and 13.7 kDa molecular-weight standards eluted.](d-64-01062-fig2){#fig2}

![Stereoviews showing structural comparisons between the isolated C~H~2 domain and similar C~H~2 regions in Fc receptor complexes. (*a*) C^α^-trace superposition of the isolated C~H~2 domain (green) and the C~H~2 domains of FcγRIII--Fc complex structures in various crystal forms: hexagonal forms (PDB codes [1e4k](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1e4k) and [1t89](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1t89), in blue and orange, respectively) and an orthorhombic form (PDB code [1t83](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1t83), magenta). The FcγRIII receptor molecules in the complexes are shown in red. Arrows point to the Fc receptor-binding sites of the C~H~2 domains. The carbohydrate moieties between the C~H~2 domains of the FcγRIII--Fc complexes are omitted for clarity. (*b*) A close-up view of one of the binding sites from the D/E loop of the C~H~2 domain, highlighting the orientation of the Tyr296 residue. (*c*) A close-up view of another binding site from the F/G loop of the C~H~2 domain is shown. Amino-acid side chains are labeled according to the orthorhombic structure (PDB code [1t83](http://scripts.iucr.org/cgi-bin/cr.cgi?rm=pdb&pdbId=1t83)).](d-64-01062-fig3){#fig3}

###### X-ray data-collection and refinement statistics for the antibody C~H~2 domain

  ------------------------------------------------- --------------------------------------------------
  Data collection                                    
   Wavelength (Å)                                   1.0
   Space group                                      *P*2~1~
   Unit-cell parameters (Å, °)                      *a* = 36.14, *b* = 40.68, *c* = 39.13, β = 106.7
   Resolution range (Å)                             26.36--1.75 (1.82--1.75)
   Observations                                     42457
   Unique reflections                               10493
   Redundancy                                       4.0 (3.0)
   Completeness (%)                                 94.4 (72.0)
    *I*/σ(*I*)                                      27.2 (7.0)
    *R*~merge~[†](#tfn1){ref-type="table-fn"} (%)   0.040 (0.129)
  Refinement statistics                              
    *R* factor[‡](#tfn2){ref-type="table-fn"} (%)   20.1 (23.6)
    *R*~free~[‡](#tfn2){ref-type="table-fn"} (%)    22.7 (31.1)
   No. of atoms: protein/water                      866/111
   R.m.s.d. bond distances (Å)                      0.006
   R.m.s.d. bond angles (°)                         1.4
   Wilson *B* value (Å^2^)                          17.0
   Average *B* values (Å^2^)                         
    Protein atoms                                   20.8
    Water O atoms                                   28.7
   Ramachandran plot                                 
    Most favored ϕ and ψ angles (%)                 95.7
    Additional allowed ϕ and ψ angles (%)           4.3
  ------------------------------------------------- --------------------------------------------------

*R* ~merge~ = .

*R* factor and *R* ~free~ = , where *R* ~free~ was calculated over 5% of the amplitudes chosen at random and not used in the refinement.
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